BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34796992)

  • 21. Fabry disease: enzyme replacement therapy.
    Bongiorno MR; Pistone G; Aricò M
    J Eur Acad Dermatol Venereol; 2003 Nov; 17(6):676-9. PubMed ID: 14761135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
    Furujo M; Kubo T; Kobayashi M; Ohashi T
    Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
    Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
    Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A possible case of carbamazepine-induced renal phospholipidosis mimicking Fabry disease.
    Chen J; Bai L; He Y
    Clin Exp Nephrol; 2022 Mar; 26(3):303-304. PubMed ID: 35059891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis.
    van der Tol L; Svarstad E; Ortiz A; Tøndel C; Oliveira JP; Vogt L; Waldek S; Hughes DA; Lachmann RH; Terryn W; Hollak CE; Florquin S; van den Bergh Weerman MA; Wanner C; West ML; Biegstraaten M; Linthorst GE
    Mol Genet Metab; 2015 Feb; 114(2):242-7. PubMed ID: 25187469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary Screening Results of Fabry Disease in Kidney Transplantation Patients: A Single-Center Study.
    Yılmaz M; Uçar SK; Aşçı G; Canda E; Tan FA; Hoşcoşkun C; Çoker M; Töz H
    Transplant Proc; 2017 Apr; 49(3):420-424. PubMed ID: 28340804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision medicine in Fabry disease.
    Lenders M; Brand E
    Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo mutation in a male patient with Fabry disease: a case report.
    Iemolo F; Pizzo F; Albeggiani G; Zizzo C; Colomba P; Scalia S; Bartolotta C; Duro G
    BMC Res Notes; 2014 Jan; 7():11. PubMed ID: 24398019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The coincidence of IgA nephropathy and Fabry disease.
    Maixnerová D; Tesař V; Ryšavá R; Reiterová J; Poupětová H; Dvořáková L; Goláň L; Neprašová M; Kidorová J; Merta M; Honsová E
    BMC Nephrol; 2013 Jan; 14():6. PubMed ID: 23305247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease.
    Avarappattu J; Gaspert A; Spartà G; Rohrbach M
    Pediatr Nephrol; 2024 Jan; 39(1):131-140. PubMed ID: 37470867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
    Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
    PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of sweat gland innervation in patients with Fabry disease: A case-control study.
    Kokotis P; Üçeyler N; Werner C; Tsivgoulis G; Papanikola N; Katsanos AH; Karandreas N; Sommer C
    J Neurol Sci; 2018 Jul; 390():135-138. PubMed ID: 29801874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fabry disease: diagnostic methods in nephrology practice.
    Vujkovac B
    Clin Nephrol; 2017 Supplement 1; 88(13):44-47. PubMed ID: 28601129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A classic variant of Fabry disease in a family with the M296I late-onset variant.
    Hirashio S; Kagawa R; Tajima G; Masaki T
    CEN Case Rep; 2021 Feb; 10(1):106-110. PubMed ID: 32902816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.